Inmed Pharmaceuticals Stock Performance
| INM Stock | USD 5.26 0.11 2.14% |
On a scale of 0 to 100, InMed Pharmaceuticals holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of -0.48, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning InMed Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, InMed Pharmaceuticals is likely to outperform the market. Please check InMed Pharmaceuticals' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether InMed Pharmaceuticals' current trending patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in InMed Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, InMed Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.14 | Five Day Return (4.54) | Year To Date Return (32.56) | Ten Year Return (99.69) | All Time Return (94.70) |
Last Split Factor 1:20 | Dividend Date 2020-07-06 | Last Split Date 2024-11-14 |
1 | InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date | 09/20/2024 |
2 | InMed Pharmaceuticals Announces Upcoming AGM Date - TipRanks | 09/26/2024 |
3 | InMed Pharmaceuticals Full Year 2024 Earnings US1.01 loss per share | 10/02/2024 |
4 | Acquisition by Adams Eric A of 11400 shares of InMed Pharmaceuticals at 1.753 subject to Rule 16b-3 | 10/14/2024 |
5 | InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board | 10/22/2024 |
6 | InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules | 11/05/2024 |
7 | InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System | 11/19/2024 |
| Begin Period Cash Flow | 8.9 M |
InMed |
InMed Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 504.00 in InMed Pharmaceuticals on September 16, 2024 and sell it today you would earn a total of 22.00 from holding InMed Pharmaceuticals or generate 4.37% return on investment over 90 days. InMed Pharmaceuticals is generating 0.2943% of daily returns assuming volatility of 6.8465% on return distribution over 90 days investment horizon. In other words, 60% of stocks are less volatile than InMed, and above 95% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
InMed Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for InMed Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as InMed Pharmaceuticals, and traders can use it to determine the average amount a InMed Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.043
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | INM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.85 actual daily | 60 60% of assets are less volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average InMed Pharmaceuticals is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of InMed Pharmaceuticals by adding it to a well-diversified portfolio.
InMed Pharmaceuticals Fundamentals Growth
InMed Stock prices reflect investors' perceptions of the future prospects and financial health of InMed Pharmaceuticals, and InMed Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InMed Stock performance.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (1.67) % | ||||
| Operating Margin | (1.57) % | ||||
| Current Valuation | (747.91 K) | ||||
| Shares Outstanding | 718.08 K | ||||
| Price To Book | 0.45 X | ||||
| Price To Sales | 0.82 X | ||||
| Revenue | 4.6 M | ||||
| Gross Profit | 1.4 M | ||||
| EBITDA | (7.06 M) | ||||
| Net Income | (7.68 M) | ||||
| Cash And Equivalents | 9.35 M | ||||
| Cash Per Share | 9.98 X | ||||
| Total Debt | 962.66 K | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.52 X | ||||
| Book Value Per Share | 1.03 X | ||||
| Cash Flow From Operations | (6.99 M) | ||||
| Earnings Per Share | 230.40 X | ||||
| Market Capitalization | 3.78 M | ||||
| Total Asset | 11.82 M | ||||
| Retained Earnings | (109.08 M) | ||||
| Working Capital | 6.72 M | ||||
About InMed Pharmaceuticals Performance
By examining InMed Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into InMed Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that InMed Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 129.88 | 3.33 | |
| Return On Tangible Assets | (0.76) | (4.61) | |
| Return On Capital Employed | 5.93 | 6.23 | |
| Return On Assets | (0.65) | (2.78) | |
| Return On Equity | (0.83) | 6.45 |
Things to note about InMed Pharmaceuticals performance evaluation
Checking the ongoing alerts about InMed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for InMed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| InMed Pharmaceuticals had very high historical volatility over the last 90 days | |
| InMed Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 4.6 M. Reported Net Loss for the year was (7.68 M) with profit before taxes, overhead, and interest of 1.4 M. | |
| InMed Pharmaceuticals has about 9.35 M in cash with (6.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| InMed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System |
- Analyzing InMed Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InMed Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining InMed Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InMed Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of InMed Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of InMed Pharmaceuticals' stock. These opinions can provide insight into InMed Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.